Insulin Pen Market to Reach USD 12 Bn in 10MM in 2022, Forecasts DPI Research in Its Topical Report Available at MarketPublishers.com
18 May 2017 • by Natalie Aster
LONDON – The insulin pen market is anticipated to surpass the USD 12 billion mark across 10MM by 2022-end. The growth of the market is being propelled by the increasing number of patients with diabetes, increased adoption rates, user–friendly design, surging popularity amid consumers, higher market demand for human insulin analogues, government support and technology advances in the domain, among others.
China has the largest number of insulin pen consumers amid the diabetic population, followed by India and Germany. The USA holds the 4th position in this regard, with Japan and Brazil following after.
With respect to users of reusable insulin pens, China is the leading consumer of reusable insulin pens. India and Germany come the second and the third, respectively, and they will likely maintain their position through the forecast period.
China is also the leader in regard to prefilled insulin pen users, with the USA and Japan following after; these three markets are expected to post the fastest growth in the forecast period.
The USA is forecast to dominate the insulin pen market, grabbing over 20% of the total market share by 2022. China and Japan are also the major markets.
Across the reusable insulin pen sector, China and Germany are projected to be the leaders, accounting for a combined market share of 75% in 2022.
In the prefilled insulin pen sector, the USA captured the biggest share of the market as of 2016, with Japan and Germany following after. The USA is poised to post the fastest CAGR in the offing.
In-demand study “Insulin Pen Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 – 2022” elaborated by DPI Research presents an all-round analysis of the market across 10 major markets (10MM) including the USA, France, Italy, Germany, Spain, Japan, the UK, China, Brazil and India.
The report sheds light on the demand in the market, canvasses the competitive scenario and trends of the top 10 insulin pen markets. It provides an all-round analysis of overall number of patients with diabetes and insulin users. It offers information on users of insulin pens, specifically focusing on reusable and prefilled insulin pen users. The study provides granular insulin pen market forecasts by value. The research publication also canvasses key growth drivers of, and restraints to the growth of the insulin pen market. Furthermore, the report includes detailed profiles of the top players operating in the insulin pen market, covering parameters like business overview, product outlook and recent trends and developments of the insulin pen marketplace.
Companies reviewed include: Novo Nordisk, Owen Mumford, Eli Lilly, Sanofi, Ypsomed and Biocon Ltd.
More in-demand market research reports by our partner can be found at its page.